New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:16 EDTHZNPHorizon Pharma price target raised to $18 from $16 at JMP Securities
JMP Securities increased its price target on Horizon as the firm reports that the company's Vimovo drug is outpacing the firm's early expectations. The firm thinks the company could increase its 2014 guidance on its upcoming Q4 earnings call. JMP Securities expects the stock to rise following the earnings, and recommends owning the shares ahead of the results. It reiterates an Outperform rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
10:13 EDTHZNPHigh option volume stocks
Subscribe for More Information
April 17, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $38 from $31 at Piper Jaffray
Subscribe for More Information
07:11 EDTHZNPHorizon Pharma Q1 results to beat expectations by wide margin, says Stifel
Stifel believes that Horizon Pharma is benefiting from strong prescription trends, and the firm says its view was bolstered by an update on prescriptions that the company gave earlier this week. Stifel raised its price target on the stock to $40 from $30 and keeps a Buy rating on the shares.
07:03 EDTHZNPHorizon Pharma receives Notice of Allowance from USPTO for Pennsaid
Subscribe for More Information
05:51 EDTHZNPStocks with implied volatility movement; ALU HZNP
Subscribe for More Information
April 16, 2015
09:18 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
April 15, 2015
18:51 EDTHZNPHorizon Pharma 15.35M share Secondary priced at $28.25
Subscribe for More Information
April 13, 2015
19:18 EDTHZNPOn The Fly: After Hours Movers
Subscribe for More Information
16:45 EDTHZNPHorizon Pharma says Duexis prescriptions up 42% in first 12 weeks of 2015
Subscribe for More Information
16:03 EDTHZNPHorizon Pharma files to sell 12M shares of common stock
Citigroup, Jefferies LLC, Cowen and Company, LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for this offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use